Perrigo enters lice market
This article was originally published in The Tan Sheet
Executive Summary
The Allegan, Mich.-based private labeler enters an agreement March 7 to expand its offerings into a new category by paying $12 mil. in cash for Qualis's store-brand pediculicide products in a transaction the firms expect to close around June 30. In a release, Perrigo President and CEO Joe Papa says the acquisition will bring "a range of products that fits nicely within our Consumer Healthcare business portfolio." The firm says adding Des Moines, Iowa-based Qualis's OTC product formulations similar to the Rid and Nix brands should increase its sales by $10 mil. annually...
You may also be interested in...
Perrigo closes Qualis deal
Perrigo completes its acquisition of Des Moines, Iowa-based store-brand pediculicide manufacturer Qualis for $12 mil. cash, the firm announces July 11. The deal, initially announced in March, gives the private labeler five OTC products equivalent to Bayer's Rid and Insight Pharmaceuticals' Nix lice products, which are expected to add more than $10 mil. to annual sales, the Allegan, Mich.-based firm says (1"The Tan Sheet" March 12, 2007, In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.